文献速递分子诊断临床微生物

粪便PCR检测幽门螺杆菌的多中心临床验证:与尿素呼气试验及商业化分子诊断的比较研究

Clinical validation of a fecal PCR assay for Helicobacter pylori detection: multicenter comparative study with urea breath test and commercial molecular diagnostics.
PubMed 文献 · J Clin Microbiol · 2026-07-27

本多中心研究纳入866例患者(777份有效样本),评估新型粪便PCR检测(Cellrun PCR assay,靶向16S rRNA)与尿素呼气试验(UBT)及商业化试剂盒的一致性。Cellrun PCR与UBT阳性率无显著差异,一致性接近完美(Kappa=0.9713),灵敏度98.2%(AUC=0.985),与商业化试剂盒性能相当。

要点

  • 粪便PCR(Cellrun)与UBT阳性率无显著差异,一致性Kappa=0.9713。
  • Cellrun PCR灵敏度98.2%(AUC=0.985),与商业化试剂盒AUC=0.983相当。
  • 治疗后灵敏度/特异度达94.74%/97.06%,干扰样本准确率100%。

核心结论

  • Cellrun粪便PCR检测幽门螺杆菌的灵敏度和特异度与UBT相当,验证了其与现有分子诊断的等效性。

研究设计与样本

  • 多中心试验纳入866例患者(2023年5月至2024年9月),来自四家医院,其中777份有效样本。
  • 比较UBT、Cellrun PCR assay(靶向16S rRNA)和商业化比较试剂(comparison reagents)的阳性检出率、诊断一致性(Kappa)及临床性能(灵敏度/特异度)。

主要发现

  • 阳性率分别为UBT 44.02%、Cellrun PCR 43.89%、比较试剂44.14%,无显著差异(P > 0.05)。
  • Cellrun PCR与UBT一致性接近完美(Kappa = 0.9713,P < 0.001),与比较试剂一致性Kappa = 0.966(P < 0.001)。
  • Cellrun PCR灵敏度98.2%(AUC = 0.985),与比较试剂(AUC = 0.983;P = 0.614)相当。
  • 弱阳性一致率为85.7%,治疗后灵敏度/特异度达94.74%/97.06%(AUC = 0.985)。
  • 干扰样本准确率100%(Kappa = 1.0);假阴性 correlates with 低细菌载量或处理变异,假阳性出现在检测阈值附近。

关键数值与推荐

  • Cellrun PCR与UBT一致性Kappa = 0.9713(P < 0.001),与比较试剂Kappa = 0.966(P < 0.001)。
  • Cellrun PCR灵敏度98.2%(AUC = 0.985),比较试剂AUC = 0.983(P = 0.614)。
  • 弱阳性一致率85.7%;治疗后灵敏度94.74%、特异度97.06%(AUC = 0.985)。
  • 干扰样本准确率100%(Kappa = 1.0)。

临床怎么用

  • 粪便PCR可作为非侵入性、无放射性替代方案用于幽门螺杆菌活跃感染检测。
  • 在资源有限环境中可提升诊断可及性,支持早期检测和靶向治疗。
  • 结果解释需注意弱阳性(一致率85.7%)及阈值附近假阳性可能。

局限性

  • 假阴性 correlates with 低细菌载量或处理变异,假阳性出现在检测阈值附近。
  • 弱阳性一致率为85.7%,提示接近检测限时结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Helicobacter pylori infection is linked to gastritis, peptic ulcers, and gastric cancer. The urea breath test (UBT), while gold standard for active infection diagnosis, poses radioactive risks and equipment dependency. Fecal molecular detection offers a non-invasive alternative but requires validation. This multicenter study evaluates a novel fecal PCR assay (Cellrun PCR assay, 16S rRNA-targeted) against UBT and a commercial kit (comparison reagents). A multicenter trial enrolled 866 patients (May 2023-Sep 2024) from four hospitals. Of 777 valid samples, positive detection rates, diagnostic consistency (kappa), and clinical performance (sensitivity/specificity) were compared across UBT, Cellrun PCR assay, and comparison reagents. Positive rates were 44.02% (UBT), 43.89% (Cellrun PCR assay), and 44.14% (comparison reagents), with no significant differences (P > 0.05). Cellrun PCR assay exhibited near-perfect agreement with UBT (Kappa = 0.9713, P < 0.001) and matched comparison reagents' consistency (Kappa = 0.966, P < 0.001). Sensitivity and specificity for Cellrun PCR assay were 98.2% (AUC = 0.985), comparable to comparison reagents (AUC = 0.983; P = 0.614). Weak-positive agreement was 85.7%, while post-treatment sensitivity/specificity reached 94.74%/97.06% (AUC = 0.985). Cellrun PCR assay achieved 100% accuracy in interference samples (Kappa = 1.0). False negatives correlated with low bacterial loads or processing variability; false positives arose near detection thresholds. Cellrun PCR assay demonstrates UBT-comparable sensitivity and specificity, validating its equivalence to established molecular diagnostics for Helicobacter pylori detection.IMPORTANCEHelicobacter pylori infection is a major global health burden, linked to gastritis, peptic ulcers, and gastric cancer. Current gold-standard urea breath tests (UBTs) carry radioactive risks and require specialized equipment, limiting accessibility. Fecal molecular detection offers a non-invasive alternative, but existing assays need robust validation. Our study validates the novel Cellrun PCR assay, showing it matches UBT's accuracy and established commercial kits. This user-friendly, non-radioactive tool enhances diagnostic accessibility, especially in resource-limited settings, enabling early H. pylori detection and targeted treatment-critical for reducing associated morbidity and mortality. Its reliability supports broader clinical adoption, advancing global efforts to manage this prevalent infection.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Wang Y, He C, Jiang Y, et al. Clinical validation of a fecal PCR assay for Helicobacter pylori detection: multicenter comparative study with urea breath test and commercial molecular diagnostics. J Clin Microbiol. 2026. PMID: 42506921. doi:10.1128/jcm.01762-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。